Payment overview · 2025
General Payments
$161.99
9 reported records · 6 companies
Healthcare provider profile · identity verified
Richard May, DO
Allopathic & Osteopathic Physicians|Family Medicine · LOOKOUT MOUNTAIN, GA · NPI 1366862229
Verified facts
What the public records show
CMS Open Payments records show Richard May, DO received $161.99 in general payments during 2025 across 9 reported records.
Supernus Pharmaceuticals, Inc. accounted for 38.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $61.79 | 38.1% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$35.48 | 21.9% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.48 | 12.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.76 | 9.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.28 | 9.4% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.20 | 8.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $161.99 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $61.79 | 3 | 2025 |
Source payment records
|
|||||
| KYPHON EXPRESS II KYPHOPAK TRAY Normalized: kyphon express ii kyphopak tray |
Device | Medtronic, Inc. | $35.48 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 103 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
103 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 318 | 84 |
| Atorvastatin Calcium | Atorvastatin Calcium | 262 | 78 |
| Lisinopril | Lisinopril | 258 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 241 | 69 |
| Gabapentin | Gabapentin | 220 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 212 | 70 |
| Sertraline Hcl | Sertraline Hcl | 194 | 52 |
| Losartan Potassium | Losartan Potassium | 180 | 53 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 179 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 177 | 65 |
| Trazodone Hcl | Trazodone Hcl | 158 | 49 |
| Omeprazole | Omeprazole | 157 | 45 |
| Meloxicam | Meloxicam | 148 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 125 | 29 |
| Clonazepam | Clonazepam | 124 | 22 |
| Tramadol Hcl | Tramadol Hcl | 115 | 24 |
| Metformin Hcl | Metformin Hcl | 113 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 111 | 27 |
| Methylprednisolone | Methylprednisolone | 108 | 93 |
| Azithromycin | Azithromycin | 105 | 78 |
| Eliquis | Apixaban | 103 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 35 |
| Celecoxib | Celecoxib | 99 | 34 |
| Cephalexin | Cephalexin | 94 | 66 |
| Prednisone | Prednisone | 92 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 51 |
| Lorazepam | Lorazepam | 90 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 89 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 88 | 35 |
| Methocarbamol | Methocarbamol | 82 | 29 |
| Simvastatin | Simvastatin | 82 | 28 |
| Memantine Hcl | Memantine Hcl | 78 | 12 |
| Buspirone Hcl | Buspirone Hcl | 77 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 19 |
| Famotidine | Famotidine | 75 | 23 |
| Montelukast Sodium | Montelukast Sodium | 72 | 25 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 71 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 67 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 23 |
| Mirtazapine | Mirtazapine | 64 | 17 |
| Spironolactone | Spironolactone | 62 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 61 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 19 |
| Carvedilol | Carvedilol | 57 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 48 |
| Ozempic | Semaglutide | 54 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 54 | 14 |
| Synthroid | Levothyroxine Sodium | 54 | 13 |
| Diazepam | Diazepam | 53 | 11 |
| Allopurinol | Allopurinol | 52 | 17 |
| Bupropion Xl | Bupropion Hcl | 52 | 18 |
| Pregabalin | Pregabalin | 52 | suppressed |
| Jardiance | Empagliflozin | 51 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 49 | 13 |
| Alprazolam | Alprazolam | 48 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 42 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 45 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 29 |
| Metformin Hcl Er | Metformin Hcl | 43 | 13 |
| Potassium Chloride | Potassium Chloride | 43 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 11 |
| Furosemide | Furosemide | 41 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | 16 |
| Naproxen | Naproxen | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 13 |
| Atenolol | Atenolol | 32 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Lamotrigine | Lamotrigine | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | 12 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 29 | 17 |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Fluconazole | Fluconazole | 28 | 21 |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 28 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 25 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Nystatin | Nystatin | 22 | 16 |
| Baclofen | Baclofen | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Cefdinir | Cefdinir | 19 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 12 |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Testosterone | Testosterone | 16 | suppressed |
| Kelnor 1-50 | Ethynodiol D-Ethinyl Estradiol | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | 11 |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 13 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Lyllana | Estradiol | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $161.99 · 9 records | Supernus Pharmaceuticals, Inc. | Auvelity, ELIQUIS, KYPHON EXPRESS II KYPHOPAK TRAY, NURTEC ODT, Qelbree, The Cologuard Plus Collection Kit, ZORYVE | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error